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A B S T R A C TBackground: We undertook a quantitative benefit-risk analysis of a
targeted isoniazid (INH) therapy for latent tuberculosis (TB) infection
for different groups of contacts of active TB cases. Methods: We
developed a decision-analytic model to compare the treatment of
latent TB infection in subgroups of contacts to no treatment over a 6-
year time horizon in a Canadian setting. Contacts were stratified into
32 groups on the basis of five binary variables: type of contact (close or
casual), tuberculin skin test (TST) results (positive or negative at 5 mm
cutoff), Bacillus Calmette-Gue´rin vaccination status, place of birth
(foreign- or Canadian-born), and age group (cutoff 35 years). Risk of TB
reactivation was calculated for each subgroup from a longitudinal
registry of contacts, adjusted for several potential confounders and
comorbid conditions. We calculated the quality-adjusted life-years
gained because of delayed or prevention of active TB via treatment of
latent TB infection versus quality-adjusted life-years lost because ofsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.006
terchange.ubc.ca.
ondence to: Larry Lynd, Collaboration for Outcomethe adverse events to INH. Results: A targeted policy based on
adopting INH therapy only in subgroups with positive expected
incremental net health benefit resulted in a different treatment
decision than the current guidelines in five subgroups comprising
3.9% of the contacts. Namely, the targeted policy comprised no INH
therapy in casual contacts with a positive vaccination history even
with a positive TST result and INH therapy in foreign-born close
contacts younger than 35 years even with a negative TST result.
Conclusions: From a benefit-risk viewpoint, INH treatment of con-
tacts should be tailored on the basis of risk assessment algorithms
that consider a range of factors at the time of screening.
Keywords: benefit-risk analysis, decision uncertainty, quality-adjusted
life-years, tuberculosis.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Despite significant reductions in the incidence of tuberculosis
(TB) in North America in the first half of the past century, there
was a resurgence in the late 1980s [1,2]. The slowed progress
toward TB elimination in recent years is in part related to the
immigration of foreign-born individuals from TB-endemic coun-
tries to industrialized countries and the increasing prevalence of
chronic diseases, both of which increase the risk of TB reactiva-
tion [3]. Thus, in the Western world, efforts to control TB are
largely focused in these subpopulations who are at an elevated
risk of advancing from latent TB infection (LTBI) to active TB
disease. An important such group is those recently exposed to
patients with active and infectious TB disease (TB contacts).
Currently in the United States and Canada, TB management
guidelines support using a cutoff of 5 mm of induration following
tuberculin skin test (TST) to identify TB contacts with LTBI who
are candidates for treatment with a 9-month course of isoniazid
(INH) [4,5].The anti-TB activity of INH was first reported in the early
1950s [6], which resulted in its widespread use for the treatment
of both active TB and LTBI. However, reports of INH-related
hepatotoxicity in the 1970s prompted the American Thoracic
Society to recommend against the use of INH therapy in those
with active liver disease or those older than 35 years unless they
were at an increased risk for progression to active TB [7]. This
recommendation was later modified to advise clinicians to
periodically monitor liver function tests in all subjects and
discontinue treatment if liver enzyme levels rose [8]. The current
Canadian standards of LTBI treatment with INH require baseline
liver function tests (transaminase levels) before INH therapy is
started, and at least monthly during therapy in those perceived to
be susceptible to liver disease [5].
Despite the substantial impact of policies and guidelines
aimed at reducing INH-induced hepatotoxicity, questions remain
concerning the trade-offs between the potential benefits and
risks of treatment of LTBI patients with INH. This trade-off is
further complicated by the differences in the risk of developingSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Research and Evaluation, 2146 East Mall, Vancouver, BC, Canada
Fig. 1 – Schematic illustration of the model. The left panel shows the decision-tree and the right panel shows the Markov
components of the model. TB, tuberculosis; INH, isoniazid; pINHStartIfOffered, probability of starting INH therapy if it is
offered to the individuals; pINHHEMinr, probability of minor, non-hepatic adverse events due to INH; pINHMinHep,
probability of minor hepatic adverse events due to INH; pINHMajHep, probability of major hepatic adverse events due to INH;
pInhStopMinrAE, probability of discontinuing INH after the occurrence of a minor adverse event; pINHComplete, probability
of completing the full course of INH therapy; pINHMajSEDie, probability of death after major adverse event due to INH;
_pReact, probability of TB reactivation (different at different nodes in the model); pDieOther, annual probability of dieing due
to non-TB causes; pATBDie, probability of death due to TB conditional on developing active TB infection.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 6 – 7 5 67active TB. In some subgroups, the risk of INH-related adverse
events can outweigh the benefits of treatment such as in those
who are at a very low risk of TB reactivation. Thus, while the
benefit-to-risk balance of INH treatment for patients at risk of
LTBI may favor treatment for some patients, the potential risks
may outweigh the benefits for others.
Quantitative benefit-risk analysis offers an objective, transparent
framework for evaluating the trade-offs between treatment-related
benefits and risks [9,10]. There have been very few studies on the
benefit-risk analysis of LTBI treatment especially with an emphasis
on segregating positive versus negative aspects of treatment [11].
Furthermore, previous studies have often failed to evaluate the
benefit of treatment in subgroups of contacts with a combination
of factors such as prior Bacillus Calmette-Gue´rin (BCG) vaccination
and ethnicity, which can be particularly useful for decisionmaking in
an era in which ‘‘personalized’’ medicine is of interest [12]. The
incorporation of benefits and risks of INH therapy into one common
metric should provide an objective evaluation to help patients,
clinicians, and policymakers make a fully informed decision.
The purpose of this study was to undertake a quantitative
benefit-risk analysis of INH for the treatment of LTBI in hypothe-
tical cohorts of TB contacts defined by several risk factors for
progression to active TB that can be easily elicited at the time of
screening. By using the incremental net health benefit framework
[13], the potential risks and benefits are combined into a common
metric (quality-adjusted life-year [QALY]) such that a positive
incremental net QALY favors INH treatment whereas a negative
value favors no treatment.Methods
Throughout this work, the word ‘‘contact’’ refers to a person
identified as having come into contact with someone who is
diagnosed with active pulmonary TB, which means that there is a
possibility of transmission, and comprises both casual and close
(household or nonhousehold) contacts.
A decision-analytic, Markov model was constructed to simu-
late the sequence of events associated with INH treatment in
adult contacts of active TB cases, and the resulting effects on
contacts’ QALYs (Fig. 1). The model was developed by using DATA
4.0 (TreeAge Software, Williamstown, MA). The time horizon of
the model was 6 years, which was selected on the basis of the
average length of follow-up of TB contacts in British Columbia(BC) from which the magnitude of the association between
specific patient characteristics and the risk of active TB was
estimated [14]. Key model assumptions are shown in Table 1.
The model starts at the time INH treatment is offered to the
individual, which is after the contact consents to receive treat-
ment and after exclusion of active TB through a chest X-ray and,
where appropriate, assessment of sputum for the presence of
Mycobacterium tuberculosis. The time cycle of the model was 1
year, during which individuals could die because of background
mortality, develop active TB, or remain free of active disease.
Individuals who develop active TB face an immediate risk of
death, and if they survive, they remain in an active TB state for
one cycle, in which the impact of the acute phase of TB on the
quality of life is modeled; they then enter the post-TB state that
simulates the long-term consequences of a previous episode of
active TB. Individuals in this state die because of other causes,
develop another episode of active TB, or remain in this state for
the rest of the time.
Hypothetical cohorts of TB contacts defined by several attri-
butes known to affect the risk of TB reactivation, that is, close
versus casual contact (a person with prolonged, frequent, or
intense contact with a TB case for more than 8 hours per day
was considered a close contact), history of BCG vaccination, place
of birth (foreign-born vs. Canadian-born non-Aboriginal), and
results of TST (positive defined as having a TST induration of Z5
mm in either the first, usually immediately following the diag-
nosis of the index TB case, or the second TST, usually planted
8–12 weeks later), were modeled. The treatment was defined as a
9-month course of INH, the recommended length of treatment in
Canada [5]. All future health outcomes were discounted at an
annual rate of 3%.Prediction Model for TB Reactivation
We used the results of our previous study in which the risk of TB
development for each subgroup of contacts was estimated from a
large, population-based, provincial registry of TB contacts in British
Columbia [14]. To capture the occurrence of active TB in contacts,
records from a 12-year period (1990–2001) were extracted, with an
average follow-up of 6 years (maximum 12.5 years). A Cox propor-
tional hazards model was developed to estimate the adjusted
hazard ratio of covariates on the risk of TB. The detailed methods
and results of this risk prediction model are published elsewhere
[14]. In brief, we modeled the 6-year cumulative incidence of active
Table 1 – Parameters used in the model.
Description of variable Base value
Distribution
type Source
6-y risk of TB in the reference group with a TST
induration of o5 mm: Canadian-born, non-
Aboriginal casual TB contacts 10–35 y of age,
no BCG vaccination, and no LTBI treatment
6.33 per 100,000 Nonparametric
bootstrap
Cox regression [14]
Hazard ratio associated with the following TB contact profile characteristics
Foreign birth 2.50 (0.27–0.59) Log normal Cox regression [14]
BCG vaccination 0.24 (0.16– 0.35) Log normal Cox regression [14]
Household contact 7.26 (4.69– 11.26) Log normal Cox regression [14]
TST induration ofZ5 mm 23.85 (14.2– 40.1) Log normal Cox regression [14]
Reduction in TB incidence due to LTBI treatment
Partially completed treatment 65% (60%–71%) Log normal Cox regression [14]
Completed treatment 94% (88%– 97%) Log normal Cox regression [14]
LTBI Treatment
Probability of completing at least 6 mo of
isoniazid
0.61 (0.59– 0.63) Binomial British Columbia Centre for
Disease Control
Probability of nonhepatic minor adverse
events
0.143 (0.122–0.165) Beta [15]
Probability of hepatotoxicity associated with INH
Probability of nonhepatitis level increase in
liver enzymes
0.15 (0.10–0.20) Beta See text
Probability of hepatotoxic adverse reaction to
isoniazid
0.00245z (0.00088–0.00687) Beta Random-effect polling of three
surveillance studies [16–18]
Probability of death due to INH hepatotoxicity
Ageo 35 y 2/202,497 Beta [19]
Age4 35 y 1/43,334
TB Disease treatment
One-year mortality given treatment of active TB
Ageo 35 yy 0.095 Fixed [2]
Age4 35 y 0.046 value
BCG, Bacillus Calmette-Gue´rin; INH, isoniazid; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test.
* No sampling variation was reported in the original study. The distribution is based on assuming that the rate is derived from 500
observations.
z Random-effect meta-analysis on the logarithm of the proportion.
y Average of values for those aged 18 to 24 y and 25 to 34 y.
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lnðHRÞ¼b0þbRx  Rcþbrx  rxþbFB  FBþbTST  TSTþbCT
CTþbBCG  BCGþbAG  AGþ    þe,
where ln(HR) is the natural logarithm of the hazard ratio, Rx and
rx are binary variables indicating whether the individual received
a full or partial course of INH, respectively, and FB, TST, CT, BCG,
and AG are binary variables that represent being foreign born,
having a TST induration ofZ5 mm, being a close contact, having
a history of BCG vaccination, and being older than 35 years,
respectively. The error term e is assumed homoscedastic and
independent across individuals. The regression equations also
had other terms (represented by ‘‘    ’’) accounting for comorbid
conditions such as chronic liver diseases, chronic alcohol use,
drug abuse, infection by human immunodeficiency virus, and
several other factors known to affect the risk of TB reactivation
[14]. In predicting the risk we assigned a value of zero to all such
variables. The reference group was therefore the Canadian-born,
non-Aboriginal, nonhousehold contacts without previous BCG
vaccination, with negative TST results, and without any major
comorbid condition that will elevate the risk of TB reactivation.
The baseline hazard for this group was estimated by using the
Breslow’s method [20] and was transformed into annual prob-
abilities of TB reactivation.Adverse Events Due to INH Therapy
Liver toxicity
Estimates of the risk of hepatotoxicity due to INH vary widely in
the literature. Mild transient elevations in liver enzymes (transa-
minases) occur in approximately 10% to 20% of the patients on
INH therapy [21,22]. Hepatitis, often defined as liver transaminase
levels exceeding five times the upper limit of normal without
symptoms or exceeding three times the upper limit of normal in
the presence of symptoms, is a much less common event. A
meta-analysis of studies evaluating INH prophylaxis (n ¼ 38,257)
published between 1971 and 1984 revealed an annual incidence
of 0.006 [23]. Conversely, a Cochrane review [24] identified only
one large, prospective study of the rate of liver toxicity associated
with INH therapy in LTBI, which reported a placebo-adjusted
probability of 0.004 [25]. There has been evidence of declining
rates of liver toxicity over the recent years, potentially attribu-
table to better monitoring [26]. As such, and given inevitable
differences between the real-world clinical settings and the
setting of a randomized trial, we believe that estimates of
hepatotoxicity rates from surveillance studies provide the most
reliable evidence. We found three surveillance studies reporting
the rate of liver toxicity in relevant patient populations [16–18].
We used a random-effects model to pool the logarithms of the
rate of liver toxicity, which yielded an overall rate of 2.45 per 1000
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 6 – 7 5 69treatment episodes (95% confidence interval 0.88–6.87 per 1000).
Given that values from as low as 1 per 1000 [26] to as high as 6 per
1000 [23] are also reported in the literature, we varied this rate
across this range in a one-way sensitivity analysis.
Death due to hepatitis has become extremely rare with
monitoring; thus, a mortality rate of 1 per 202,246 and 1 per
43,334 contacts initiating INH treatment for those younger than
35 years and those 35 years of age and older, respectively, was
used on the basis of data from large surveillance studies [19].
Other INH-related adverse events
Mild adverse events associated with INH therapy including
limited rash, nausea, malaise, fever, nervousness, and headache
are common [27,28]. Because studies have used different terms
and definitions for these adverse reactions, the estimation of
their incidence is problematic. Given that these adverse events do
not generally require the discontinuation of treatment in most
cases, we used a composite of ‘‘minor adverse reaction’’ as a
single category encompassing all minor, nonhepatic adverse
events. We assumed an overall rate of 14.3% for such events
during the 9 months of therapy [15].
INH efficacy and compliance
Based on the BC treatment data, only 60% of the contacts who are
offered INH therapy initiate treatment and 61% of the contacts
who initiate INH therapy complete the full 9 months of treat-
ment. We assumed that those who do not complete therapy
receive 3 months of treatment before discontinuing, and thus
receive only partial benefit of treatment (Table 1). From theseTable 2 – Assumptions for utilities and time spent in tuberculo
Health state SF-6D Utility HUI-3
‘‘No infection’’ (no TB
disease or LTBI
therapy)
Beta with a mean of
0.82  0.015
Beta with
0.90
Disutility of LTBI
therapy with no
adverse reaction
0 (0.02 in sensitivity
analysis)
0 (0.0
Disutility of elevated
liver enzyme
(nonhepatotoxic level)
during LTBI treatment
0.09  0.01 0.09
Disutility of hepatotoxic
reaction during
treatment for LTBI
0.333  0.05† 0.33
Disutility of other
adverse events due to
treatment for LTBI
0.087  0.025 0.027
Disutility of active TB
disease
0.13  0.025 0.16
After successful
treatment of active TV
0.065 (uniform
distribution 0 and
disutility of active TB
disease)
0.08 (unif
distribut
disutility
disease )
Death 0
HUI, health utilities index; LTBI, latent tuberculosis infection; SF-6D, si
health survey).
* In the rare event that a draw from the beta distribution (in the course o
value of 0 was assigned.
† Compared with the United Kingdom population norm values for SF-6D
because of uncertainty in the similarity of health conditions.data, we estimated that contacts receiving partial therapy have a
65% lower risk of TB reactivation and those who receive the full
course have a 94% lower risk of TB reactivation, compared with
those who did not receive any treatment.
Other transition probabilities
Age-specific, all-cause mortality was based on Canadian Life
Tables [29]. Mortality from TB disease was also taken into account
as reported in the literature (see Table 1) [2].
Health states and utilities
Key assumptions relating to the construction of QALYs are
presented in Table 2. Health state utility values (HSUVs) were
estimated from the literature and also elicited with six-
dimensional health state short form (derived from short form
36 health survey) (SF-6D) and health utilities index 3 question-
naires given at baseline and at months 3 and 6 to 119 patients
with LTBI and 114 patients with active TB recruited through BC
TB clinics in 2004 to 2005 [30,31]. We assumed that contacts who
with a negative TST result and those with a positive TST result for
whom INH therapy is not recommended will have the same
HSUV as the general population. The SF-6D HSUVs were used in
the base-case analysis and the health utilities index 3 HSUVs in
sensitivity analysis. We used the trapezoidal rule for calculating
HSUVs of patients during the treatment of LTBI and TB (implicitly
assuming that the HSUV varies linearly between measurements).
We are not aware of any reports in the literature that show the
reduction in HSUV associated with receiving a diagnosis of LTBI
in the absence of any adverse event. In the base-case analysis, wesis (TB) health states.
Utility Duration Reference
a mean of
 0.21
Remainder of time while
alive
[30,31]
2  0.01) 3 mo (if patient is
noncompliant) 9 mo
(if patient is
compliant)
[30,31]
 0.01 3 mo [32]
3  0.05† 2 mo (if patient survives)
1 mo (if patient dies)
[33,34]
 0.025 1 mo [35]
 0.036 6 mo (if patient survives)
3 mo (if patient dies)
[30,31]
orm
ion 0 and
of active TB
Remainder of time while
alive
Assumption
0 By definition
x-dimensional health state short form (derived from short form 36
f a Monte Carlo simulation) resulted in a utility value of less than 0, a
. HUI was not available for this value. The SD was inflated by 100%
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diagnosis of LTBI and INH treatment without any adverse events.
Guo et al. [30] measured and reported all eight short form 36
health survey domains in patients with LTBI who were receiving
treatment (Guo et al., 2010, personal communication). In a
sensitivity analysis, we calculated the decline in quality of life
for contacts on treatment by comparing the decline in each
domain of the short form 36 health survey with those of the
Canadian population [36] and mapped this to a decline in HSUVs
by using the equations derived by Ara and Brazier [37]. We
assumed that the HSUV of LTBI patients after completing INH
therapy returns to normal [38]. For active TB patients, as reported
by others [31,39], we assumed that their quality of life remains
low following the completion of treatment. Given the possibility
of treatment-related side effects and the stigma attached to the
diagnosis of TB, a reduction in quality of life can last for extended
periods well beyond the completion of treatment; nevertheless,
there does not seem to be any study on HSUVs after treatment
completion [40]. Without such evidence, in the base-case analy-
sis, we assumed that the HSUV at the end of treatment will
remain the same till the end of year one, and will be the midpoint
of this value and the utility of the normal population afterward.
Similarly, we were unable to identify an estimate of HSUV for
patients experiencing INH-related hepatotoxicity. We therefore
incorporated a published SF-6D HSUV estimate derived from a
sample of patients undergoing hepatitis-related liver transplan-
tation (0.61, standard error 0.01) [33]. Time spent in these health
states was determined from another TB cost-effectiveness
analysis and permitted the calculation of QALYs [41]. We also
used HSUVs for minor adverse events (disutility of 0.087 as
measured by the SF-6D and 0.027 as measured by the health
utilities index 3, lasting for 3 months) from another study [35].
Benefit-Risk Analysis
The three outcomes of the model were the QALYs gained from
LTBI treatment, QALYs lost because of the adverse events of INH
and because of active TB cases, and the incidence of active TB.
These outcomes were calculated for each intervention (however,
INH adverse events apply only to the INH strategy; therefore, the
no-INH strategy always has zero QALY loss due to INH) and were
reported per 1000 contacts.
Results of the benefit-risk analysis within each of the 32
subgroups can be used to formulate a targeted policy on the
basis of picking, within each subgroup, the strategy that results
in the highest net QALY gain. The health outcomes associated
with such a targeted policy are the weighted-average of the
outcomes of the selected within-subgroup strategies with
weights being the relative prevalence of each subgroup in the
target population. In other words, if Pi represents the relative
prevalence of the ith subgroup among the total population of TB
contacts, and Xi is the outcome of the strategy that has the
maximum net QALY gain in this subgroup, then the relevant
outcome for the targeted policy can be calculated as follows:
X¼
X32
i¼1
PiXi
The weights Pi were directly estimated from the database at
BC Centre for Disease Control (see the Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2012.09.006). We used the
above equation for calculating the QALY gain, QALY loss, and TB
incidence for the targeted policy and for the status quo policy of
providing INH therapy to those who have a positive TST result.
For clarity and brevity of results, subgroup-specific results
were reported only for subgroups in which the targeted policy
resulted in a different decision than the status quo policy. Full
outcomes for each of the 32 subgroups are provided in theAppendix in Supplemental Materials found at doi: 10.1016/
j.jval.2012.09.006.
Probabilistic Sensitivity Analysis and Expected Value of
Information Analysis
All uncertain parameters in the model were assigned probability
distributions that were either estimated directly from the data
provided in the original study, modeled so that the corresponding
confidence interval matched the reported value, or were based on
assumptions if specific estimates were not available in the
literature. The uncertainty around parameters estimated from
the proportional hazard model was taken from the covariance
matrix of the regression coefficients as a joint multivariate
normal distribution. After all uncertain parameters were
assigned a probability distribution, we randomly drew from such
parameters and calculated risk and benefit outcomes. Such
calculations were repeated 1000 times. The results were used to
calculate the probability of each strategy being the best option
within each subgroup, to draw the risk-benefit plane, and for the
value of information analysis.
The expected value of perfect information for QALYs (EVPIQ)
was defined as the expected gain in net QALYs when the
uncertainty of all model parameters was resolved. It can be
calculated as follows:
EVPIQ¼EO½max DQðOð ÞÞmax½EO DQðOð ÞÞ,
where O is the set of all stochastic model parameters, DQ is the
net QALY gain (as a function of model parameters), and the
maximization step is performed across the two strategies of
treatment/no treatment. EVPIQ was calculated for each subgroup.
The EVPIQ for the targeted policy is the weighted-average of the
subgroup-specific EVPIQs, with weights being the relative preva-
lence of each subgroup in the population.Results
From 1990 to 2001, 26,542 TB contacts were traced in BC, of which
180 developed active TB, resulting in an incidence rate of 678 per
100,000 person-years. The results of the regression analysis on
these data and the corresponding risk prediction model used for
the present analysis are described in detail elsewhere [14].
The status quo policy of providing INH therapy to individuals
with a positive TST result resulted in 176 instances of INH
therapy per 1000 contacts. However, the targeted policy, formu-
lated on the basis of providing INH only to subgroups with a
positive net QALY gain between INH and no-INH strategy,
resulted in 159 instances of treatment per 1000 contacts. The
targeted policy led to a different recommendation than the status
quo policy in 3.9% of the contacts (Table 3). One subgroup was
foreign-born close contacts younger than 35 years with a nega-
tive TST result and without previous BCG vaccination. In this
subgroup, the targeted policy recommends INH therapy despite a
negative TST result. However, in casual contacts with a positive
BCG history, regardless of the place of birth, age, and BCG status,
the targeted policy recommends no INH therapy even when the
TST result is positive.
The incidence of active TB over the next 6 years after screen-
ing was 6.927 and 6.932 per 1000 contacts for the status quo and
the targeted policy, respectively. The slightly higher incidence of
TB in the targeted policy was due to not providing INH therapy to
some subgroups among which the status quo policy recommends
treatment. This resulted in the targeted policy being associated
with an incremental net QALY loss due to active TB of 0.0027 per
1000 contacts but an incremental net QALY gain of 0.0583 due to
lower INH-related adverse events. The overall incremental net
Table 3 – QALY gain, QALY loss, incidence of TB per 1000 contacts of INH and no-INH therapy in subgroups that the targeted
policy is different than the status quo policy.
Subgroup
Proportion
of all
contacts
INH No INH Incremental
net QALY
gain of INH
vs no-INH
therapy
QALY
gain
QALY
loss
Active
TB
cases
QALY
gain
QALY
loss
Active
TB
cases
Foreign-born close contacts
older than 35 y, with a
negative TST result and
negative vaccination history
1.2% 4525.17 3.77 17.87 4514.05 0.00 33.59 7.35
Canadian-born casual
contacts, positive history of
vaccination and a positive
TST result, younger than 35 y
1.0% 4537.82 3.77 0.07 4537.84 0.00 0.13 3.79
Canadian-born casual
contacts, positive history of
vaccination and a positive
TST result, 35 y or older
0.8% 4563.31 3.44 1.71 4562.25 0.00 3.22 2.38
Foreign-born casual contacts,
positive history of
vaccination and a positive
TST result, younger than 35 y
0.5% 4537.75 3.77 0.18 4537.69 0.00 0.34 3.71
Foreign-born casual contacts,
positive history of
vaccination and a positive
TST result, 35 y or older
0.4% 4561.47 3.44 4.28 4558.79 0.00 8.06 0.76
All other subgroups 96.1% 4547.90 3.59 6.43 4543.90 0.00 12.07 0.01
INH, isoniazid; TB, tuberculosis; TST, tuberculin skin test; QALY, quality-adjusted life-year.
* Bold cells delineate the strategy that is recommended in the targeted policy. The other strategy is adopted in the status quo policy.
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therefore 0.0556 per 1000 contacts. Considering the population in
which the targeted policy resulted in a different treatment
decision, this value corresponds to an incremental net QALY gain
of 1.43 per 1000 contacts. The subgroup that benefits the most
from INH therapy was foreign-born close contacts younger than
35 years who have a positive TST result and a negative BCG
history in which INH therapy results in a QALY gain of 73.9 versus
a QALY loss of 3.4 (incremental net QALY gain ¼ 70.5) per 1000
contacts over 6 years. Conversely, the group that benefits the
least from INH treatment is Canadian-born casual contacts older
than 35 years who have a negative TST result and a positive BCG
history. INH therapy in this group results in a QALY gain of less
than 0.01 due to aversion of active TB and a QALY loss of 3.8 due
to INH therapy (net QALY loss of 3.8) per 1000 contacts.Deterministic Sensitivity Analysis
The impact of several alternative assumptions on the composi-
tion of the targeted policy and its associated outcomes is
illustrated in Table 4. The results are presented as relative
changes in the targeted policy as a function of change in the
underlying model parameters. The recommendation of providing
INH therapy to foreign-born close contacts older than 35 years
with a negative TST result and negative vaccination history was
sensitive to the underlying assumption. For example, this recom-
mendation was not net beneficial when the TB reactivation rate
or INH efficacy was lowered, or when the liver toxicity rate was
increased. However, when the risk of TB reactivation was
increased by 50%, INH became cost-effective in foreign-borncasual contacts older than 35 years with a positive BCG history
and a positive TST result.
Similarly, alternative assumptions for HSUVs influenced the
optimal strategy within subgroups. Specifically, the results were
sensitive to the assumption that INH therapy even without
adverse events reduced quality of life. With such an assumption,
INH therapy was no longer net beneficial in several subgroups
including casual contacts with a positive TST result, regardless of
age and place of birth, and in Canadian-born close contacts with
a positive BCG status and TST result. However, assuming that
minor, nonhepatic adverse events of INH do not reduce quality of
life resulted in INH becoming net beneficial in BCG-negative
foreign-born casual contacts 35 years or older with a negative
TST result (Table 4).
Probabilistic Sensitivity and Expected Value of Information
Analyses
Figure 2 demonstrates the results of probability sensitivity
analysis for the targeted policy versus the status quo policy as
the scatter plot of incremental net QALY gains and losses in the
left panel and the distribution of the incremental net QALY gains
in the right panel (both results are per 1000 contacts). The
distribution of net QALY gains is right-skewed, with a mean of
0.060 and a median of 0.057. Only in 3 of the 1000 simulations
(0.3%), the incremental net QALY gain of the targeted versus
status quo policies was less than zero, reflecting the high
confidence in the targeted policy having an overall positive
incremental net health benefit. The scatter plot of the joint
incremental QALYs gained (x axis) and QALYs lost (y axis)
revealed that in the vast majority of instances the incremental
Table 4 – Results of the deterministic sensitivity analysis.
Scenario Change in the targeted policy Net QALY gain per
1000 contacts
(targeted vs.
status quo policy)
Additional groups requiring INH therapy Additional groups not requiring INH therapy
Risk (hazard) of TB reactivation
50% lower None Foreign-born close contacts older than 35 y, with a negative TST
result and negative vaccination history (#12), Canadian-born
casual contacts with a positive TST result (#2, #3)
0.025
50% higher BCG-negative foreign-born casual contacts with
a negative TST result (#27)
None 0.07
INH efficacy†
50% lower None Foreign-born close contacts older than 35 y, with a negative TST
result and negative vaccination history (#12)
0.059
50% higher None None 0.055
Discount rate
0% None None 0.055
5% None Foreign-born close contacts older than 35 y, with a negative TST
result and negative vaccination history (#12)
0.058
Risk of liver toxicity
0.001 Foreign-born close contacts older than 35 y, with
negative BCG history and a negative TST result
(#11)
None 0.061
0.006 Canadian-born casual contacts, BCG negative,
older than 35 y, positive TST result (#3)
Foreign-born close contacts older than 35 y, with a negative TST
result and negative vaccination history (#12)
0.059
HUI3 instead of SF-6D HSUVs None None 0.055
No disutility due to INH minor
adverse events
BCG-negative foreign-born casual contacts 35 y
or older with a negative TST result (#27)
None 0.049
Disutility of 0.02 (SF-6D) due to
INH therapy, without
adverse events
None Casual contacts with a positive TST result, regardless of age and
place of birth (#2, #3, #10, #11), Canadian-born close contacts
with positive BCG and TST result (#22, #23)
0.811
No disutility after treatment of
active TB
None Casual contacts with a positive TST result , regardless of age and
place of birth (#2, #3)
0.086
Disutility due to INH major
adverse events
Half of the point estimate None None 0.051
Twice as the point estimate None Foreign-born close contacts older than 35 y, with a negative TST
result and negative vaccination history (#12)
BCG, Bacillus Calmette-Gue´rin; HSUV, health state utility value; HUI 3, health utilities index 3; INH, isoniazid; TB, tuberculosis; SF-6D, six-dimensional health state short form (derived from
short form 36 health survey); TST, tuberculin skin test; QALY, quality-adjusted life-year.
* List of all subgroups by numbers is available in Appendix Table A1.
† Defined as relative change in the estimated hazard ratio of INH treatment (both partial and complete) from the COX regression model.
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Fig. 2 – Left: Distribution of the incremental QALY gain (horizontal axis) vs. incremental QALY loss (vertical axis) for the
targeted versus status quo policies across the population. Probabilistic sensitivity analysis (PSA). Right: Distribution of the
incremental net QALY gain for the targeted versus status quo policies across the population. The oblique line depicts the line
of equality (Y=X). The vertical line indicates zero incremental net QALY gain.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 6 – 7 5 73QALYs loss due to INH fell below the x axis (because the y axis
presents net QALY loss, a negative value indicates net QALY gain),
meaning that the targeted policy results in gain in QALY due to
reducing INH-related adverse events. In 58% of the simulations,
the points were on the right side of the y axis, indicating that
there is a 58% chance that the targeted policy is associated with
an incremental QALY gain due to the aversion of active TB by
adopting the targeted policy.
The overall EVPIQ was 0.054 per 1000 contacts. That is,
currently, 0.054 QALYs are on average missed per 1000 contacts
because of our uncertainty in model parameters. This is in the
same range as the incremental net QALY gain between the
targeted and status quo policies in the base-case analysis,
roughly indicating that the performance of a targeted policy (in
terms of incremental net QALY gain of the status quo policy)
formulated with perfect information will be twice better as the
currently formulated targeted policy.
In 11.1% of the contacts, there was more than 90% probability
that INH therapy is associated with a positive incremental net
QALY gain while in 82.1% of the contacts, there was greater than
90% probability that INH is associated with an incremental net
QALY loss. Subgroup-specific values for EVPIQs and the probabil-
ity of INH therapy being the optimal strategy are provided in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2012.09.006. A clear and expected pattern emerged by comparing
EVPIQ with the probability of a positive incremental net benefit
associated with INH therapy within subgroups: for subgroups for
which the probability of a positive incremental net health benefit is
either very high (near 1) or very low (near 0), one can be relatively
certain that the correct decision is being made to treat or not treat
and hence the associated opportunity loss is low. Conversely, in
subgroups in which the probability of a positive incremental net
benefit is far from 0 or 1, the opportunity loss increases given the
increased likelihood of making the wrong decision.Discussion
In this study, the risk and benefit of treatment of LTBI with INH
was examined on subgroups of TB contacts based on the
combination of factors that were perceived to be easily verifiable
in TB contacts and to shift the risk-benefit trade-off. Such shiftcan presumably happen through the baseline risk of infection
(foreign-born vs. Canadian, close vs. casual contacts), the risk of
TB reactivation (BCG vaccination), and the risk of adverse events
due to INH (age). We found that compared with the current
strategy of providing LTBI therapy to those with positive TST
results, a targeted policy that considers such variables results in a
net QALY gain of 0.0556 per 1000 contacts, or 1.43 QALYs in
contacts in which the recommendation based on the targeted
policy is different than that of the status quo policy. Although
such increase in QALY seems small, because the elicitation of
such covariates used for our analysis is easy, this gain in the
outcome comes at very little cost. Of interest, such a targeted
policy consisted of providing treatment to several subgroups of
contacts with negative TST results. These are the subgroups with
a high prevalence (pretest probability) of LTBI such that the
likelihood of LTBI (posttest probability) even with a negative
TST result remains high enough that justifies LTBI treatment.
To our knowledge, our study is one of the first that shows that
underlying risk factors might justify treatment in some sub-
groups even with negative screening results. This is despite using
the low cutoff of 5 mm with a high negative predictive value
among contacts without comorbid conditions. In jurisdictions
that use higher TST cutoffs, or among individuals with an
elevated background risk of TB reactivation, INH therapy without
screening might be net beneficial in additional subgroups.
In this study, we attempted to be systematic and transparent
by using recent developments in the benefit-risk methods and
probabilistic analysis of uncertainty in the health economics and
risk analysis literature [35,42–44]. We demonstrated that some
factors that can easily be elucidated in contacts of active TB cases
at the time of screening can be used to inform individualized
treatment decisions. As such, the findings of our study can be
used to refine the current contact tracing standards in BC and by
extension in other low-prevalence jurisdictions. Similar methods
can also be used to apply this model in different settings.
Consideration of the benefit-risk trade-off is an integral part of
the approval process for new medications, yet the process suffers
from lack of transparency and objectivity [42]. The methods used
in this analysis provide a framework for an objective, compre-
hensive analysis of available evidence in considering both poten-
tial benefits and risks of an existing or emerging treatment.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 6 – 7 574The present analysis is also one of the first that brings the
expected value of information methodology into the benefit-risk
analysis literature, as recommended by Garrison et al. [42]. We
quantified the potential opportunity loss due to uncertainty in
the parameters of our model in terms of the potential QALYs lost
per individual. Expected value of information analysis has mainly
been on the net monetary benefit scale. This allows direct
comparison of the EVPI with the cost of the future study to act
as an objective criterion on the merit of further research. A
benefit-risk analysis is agnostic to costs and hence does not
involve the calculation of the monetary net benefit. The net QALY
gained, however, can be regarded as a net health benefit when
the decision maker has an infinite value for willingness to pay,
that is, prefers the strategy that maximizes the net health gain
independent of its costs.
INH has been the current mainstay of treatment for LTBI, and
the data that have been incorporated into the model are therefore
timely [5]. There are emerging alternative treatments, however,
for LTBI that are not captured in our database and thus, we were
unable to compare INH with newer LTBI treatments [43,44]. In
addition, there are newer screening tools, notably the interferon-
gamma release assays that have several advantages over TST,
including better specificity especially in BCG-vaccinated indivi-
duals as well as more reliable administration and interpretation
[45]. From a pure benefit-risk perspective, the use of interferon-
gamma release assay in place of TST will most likely be asso-
ciated with an overall benefit. Nevertheless, interferon-gamma
release assays are generally more expensive, and recent studies
have shown that in important subgroups of individuals at an
elevated risk of LTBI, TST remains the cost-effective choice [46].
Overall, our analysis was conducted to quantify the benefits
associated with ‘‘fine-tuning’’ currently established LTBI screen-
ing programs (by personalizing the decision to offer a standard
treatment based on individual-level covariates). If the goal is to
comprehensively inform treatment guidelines considering the
new developments in screening and treatment technologies, a
full cost-effectiveness analysis will be required. Such an analysis
will expand the present study by including all relevant screening
and treatment options, and incorporating costs in the valuation
of competing strategies, factors that need to be considered if the
stage is set for major policy changes. However, as long as INH
therapy based on TST screening is concerned, our analysis
provides important insights into the health benefits of persona-
lizing such a strategy.
The limitations of our study should be acknowledged. Our
estimation of the protective effect of INH was based on admin-
istrative data, and the 94% protection figure in fully compliant
individuals without any risk factor might be an overestimate. One
potential confounding factor is the ‘‘healthy user effect’’ [47]. In
the present context, this means that patients who remain
compliant during the full course of INH therapy generally follow
a healthier lifestyle than do those who discontinue the follow-up,
and as such might be less susceptible to develop active TB (or TST
might have a lower positive predictive value in such individuals
to begin with). Furthermore, we were limited to the recorded
variables in our database, but arguably there are several more
variables that can easily be verified at the time of screening and
can be used to further fine-tune the treatment decision for TB
contacts [48,49]. We were also limited to a single cutoff of 5 mm
for this study, while stratification of the population based on
other TST cutoffs (e.g., 10 mm and 15 mm) might have resulted in
more refined strategies with avoidance of therapy to some
contacts whose TST is above 5 mm but below higher thresholds.
We did not model secondary cases of TB that might arise in
contacts of the person during the time gap between TB reactiva-
tion and resolution of infectivity either spontaneously or with
treatment. A realistic modeling of such spread of TB in thecommunity stipulates different modeling paradigms that are
capable of modeling the dynamic transmission of infection [50].
We also did not model the possible psychological effects of the
diagnosis of LTBI or active TB in relatives of the individual
undergoing treatment. Furthermore, the observed benefit in
several subgroups was small, and while a risk-neutral analysis
will recommend the intervention with the highest expected
benefit no matter the magnitude of such benefit [51], it is argued
that because of deviations from risk-neutrality in practice, there
must be a margin of benefit for a decision to justify its imple-
mentation [42].
Patients, health professionals, and policymakers all alike
have to make decisions regarding individual or public health in
the presence of uncertainty. Quantitative evaluation of the
potential benefits and risks of existing and emerging health
technologies makes the elements of the decision more explicit
and transparent, thus providing the decision maker with an
unbiased and informative decision aid. The literature on quan-
titative benefit-risk analysis is still evolving; however, this
application demonstrates that in specific groups of patients,
the potential benefits outweigh the potential harms and thus,
identifies those subgroups for which INH treatment of LTBI
should be indicated.
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